12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Efavirenz/lamivudine/tenofovir disoproxil fumarate regulatory update

Aurobindo said late last month that FDA granted tentative approval to efavirenz/lamivudine/tenofovir disoproxil fumarate tablets alone or in combination with other antiretrovirals to treat HIV-1 infection. The fixed-dose combination of 600 mg efavirenz, 300 mg lamivudine and 300 mg tenofovir is eligible...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >